Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

BioNTech SE

Pfizer

You'll have a much better shot at getting a shot next year.

3 Reasons Why You Probably Won't Receive a Coronavirus Vaccine Shot by the End of 2020

Shares of Moderna Inc. MRNA, +2.93% gained 3.8% in premarket trading on Thursday after the company said it plans to start developing a seasonal flu vaccine.

Moderna to start developing a seasonal flu vaccine

Moderna should have enough data from its late-stage trial to know whether its coronavirus vaccine works in November, CEO Stephane Bancel said.

Moderna expects to know if its coronavirus vaccine works by November, CEO says

Novavax

These two coronavirus vaccine contenders have dramatically different product development prospects.

Better Coronavirus Stock: Moderna vs. Novavax

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces progress across broad portfolio and all three clinical stage therapeutic areas at 2020 R&D Day.

Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day

Vertex Pharmaceuticals

CAMBRIDGE & BOSTON, Mass.--(BUSINESS WIRE)--Moderna and Vertex establish new collaboration to treat cystic fibrosis using gene editing.

Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing

CAMBRIDGE, Mass. & PARMA, Italy--(BUSINESS WIRE)--Moderna and Chiesi Group establish collaboration to discover and develop mRNA therapeutics for pulmonary arterial hypertension (PAH).

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

Moderna, Inc.: All Signs Point To An Impending Rally

Its new operations in Switzerland will boost its EU presence as it aims to bring a COVID-19 vaccine to market worldwide.

Moderna Opens Its First Commercial Office in Europe

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) announced Wednesday that it is pursuing expansion of commercial operations outside North America for the first time.

What's Significant About Moderna's Expansion Outside North America

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first commercial organization outside North America in Switzerland

Moderna Announces First Commercial Organization Outside North America in Switzerland

Bristol-Myers

CytoDyn Inc.

Gilead Sciences

Immunomedics

Inovio Pharmaceuticals

Mesoblast

Sorrento Therapeutics Inc

Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles

With the race to find an effective vaccine tightening, MRNA stock just might have the inside lane due to lingering question marks about competing vaccine types. If so, Moderna can also do much good in addressing racial conflict in America.

With Its Vaccine Trail, Moderna Addresses Racial Disparity Head On

Our indicative theme of Coronavirus Vaccine stocks - which includes a diverse set of U.S. based pharma and biotech companies that are working on novel Coronavirus vaccines - is up by over 600% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 3%.

Moderna, Novavax, Pfizer: Coronavirus Vaccine Stocks Poised To Recover From Recent Sell Off?

Morgan Stanley

Moderna, Inc. (MRNA) CEO Stéphane Bancel at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

CureVac B.V

GlaxoSmithKline

Johnson & Johnson

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. 
AstraZeneca (NYSE:AZN)
CureVac (NASDAQ:CVAC)
GlaxoSmithKline (NYSE:GSK)
Inovio (NASDAQ:INO)
Johnson & Johnson (NYSE:JNJ)
Moderna (NASDAQ:MRNA)
Novavax (NASDAQ:NVAX)
The post 7 Coronavirus Vaccine Stocks to Watch as Approval Nears appeared first on InvestorPlace.

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

Moderna Inc (NASDAQ: MRNA), which is one of the three companies outside of China to have moved its coronavirus vaccine candidates into late-stage trials, is close to completing targeted enrollment into the study.

Moderna's Late-Stage Coronavirus Vaccine Study Hits 78% Enrollment

Moderna Slowed Enrollment in Its Phase 3 Coronavirus Vaccine Clinical Trial

The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.

What If More Than One Company Wins the Coronavirus Vaccine Race?

The company's wild year doesn't make up for its long-standing issues.

Why I'll Never Own Moderna Stock

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

Merck

Companies could only distribute the vaccine internationally if domestic need is met.

Senate Considers Bill to Block International Distribution of Coronavirus Vaccine

A fresh executive hire by the company is a good sign of potentially bright days ahead.

Why Shares of Moderna Rose While the Market Tanked on Thursday

AstraZeneca's pause in key Covid vaccine testing, after a participant fell ill, boosted shares of rival vaccine makers Moderna and Novavax for a second day amid the push to end the pandemic.
The post Covid Report: AstraZeneca Fallout Continues To Propel Moderna, Novavax Stock appeared first on Investor's Business Daily.

Covid Report: AstraZeneca Fallout Continues To Propel Moderna, Novavax Stock

The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.

News for Moderna Stock (MRNA)